Standout Papers

Phase III Study of Afatinib or Cisplatin Plus Pemetrexed... 2004 2026 2011 2018 2.4k
  1. Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations (2013)
    Lecia V. Sequist, James Chih‐Hsin Yang et al. Journal of Clinical Oncology
  2. Direct Activation of Bax by p53 Mediates Mitochondrial Membrane Permeabilization and Apoptosis (2004)
    Jerry E. Chipuk, Tomomi Kuwana et al. Science
  3. Tumor Regression in Cancer Patients by Very Low Doses of a T Cell–Engaging Antibody (2008)
    Ralf C. Bargou, Eugen Leo et al. Science
  4. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6 (2015)
    James Chih‐Hsin Yang, Lecia V. Sequist et al. The Lancet Oncology
  5. Phosphatidylinositol 3-Kinase α–Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study (2018)
    Dejan Juric, Jordi Rodón et al. Journal of Clinical Oncology
  6. FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma (2021)
    Uğur Şahin, Ö. Türeci et al. Annals of Oncology
  7. Pan-cancer efficacy of pralsetinib in patients with RET fusion–positive solid tumors from the phase 1/2 ARROW trial (2022)
    Vivek Subbiah, Philippe A. Cassier et al. Nature Medicine

Immediate Impact

13 by Nobel laureates 23 from Science/Nature 99 standout
Sub-graph 1 of 19

Citing Papers

Computational design of soluble and functional membrane protein analogues
2024 StandoutNatureNobel
Cancer biomarkers: Emerging trends and clinical implications for personalized treatment
2024 Standout
4 intermediate papers

Works of Martin Schüler being referenced

Plasma Next Generation Sequencing and Droplet Digital-qPCR-Based Quantification of Circulating Cell-Free RNA for Noninvasive Early Detection of Cancer
2020
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations
2013 Standout
and 2 more

Author Peers

Author Last Decade Papers Cites
Martin Schüler 9451 7013 8758 465 19.9k
William D. Figg 9855 4342 11342 599 24.6k
Jennifer R. Grandis 9884 4844 10189 341 21.5k
Gary K. Schwartz 11072 7272 8340 436 20.5k
Patricia LoRusso 10965 4274 10660 560 21.3k
Giampaolo Tortora 13500 7644 9748 619 23.7k
Peter J. O’Dwyer 12800 5123 9732 394 23.0k
Kenneth J. O’Byrne 12402 10276 8206 586 23.0k
Julian R. Molina 10277 7942 6099 211 17.8k
Nicola Normanno 10221 5459 8217 354 18.0k
Masakazu Toi 10580 5860 7817 651 20.9k

All Works

Loading papers...

Rankless by CCL
2026